The combination of DLS with microfluidic components enables direct feedback during the production of nanoparticles. This allows particle sizes to be controlled precisely and formulations to be developed more efficiently.
Inline and online analysis with flowDLS not only reduces time and costs by eliminating offline sampling, but also increases product safety and reproducibility.
Fraunhofer IMM combines flowDLS with continuous synthesis processes to produce nanoparticles with defined properties. This includes adapting particle size, shape, and surface functionalization for specific applications. Real-time analysis enables immediate adjustment of synthesis parameters, resulting in higher reproducibility and efficiency.
Due to their solubility properties, many modern pharmaceutical agents are difficult to make bioavailable in the human body using traditional dosage forms. Bioavailability means that the active ingredient is available unchanged in the body's system. Bioavailability characterizes both the speed and extent of availability at the site of action.